Vimarsana
Biggest News Aggregation in the World

Page 6 - Roberte Hoffman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Roberte Hoffman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Roberte Hoffman Today - Breaking & Trending Today

Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study - Vimarsana News

Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study

By pausing the REM-001 program, the Company expects to save approximately $3.0 million through 2023.

Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study - Vimarsana News

Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

Kintara Therapeutics Announces Fiscal 2022 Financial Results and Provides Corporate Update - Vimarsana News

Kintara Therapeutics Announces Fiscal 2022 Financial Results and Provides Corporate Update

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

Antibe Announces Results of 2022 Annual Meeting - Vimarsana News

Antibe Announces Results of 2022 Annual Meeting

TORONTO--(BUSINESS WIRE)--$ATBPF--Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held ear...

Kintara Therapeutics Receives Study May Proceed Letter from the FDA for REM-001 for Cutaneous Metastatic Breast Cancer - Vimarsana News

Kintara Therapeutics Receives Study May Proceed Letter from the FDA for REM-001 for Cutaneous Metastatic Breast Cancer

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...